3,4,5,6-tetramethylsalicylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4,5,6-tetramethylsalicylic acid
• 英文别名: 2-Hydroxy-3,4,5,6-tetramethylbenzoic acid
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: NROHFRUHGBUHAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丁酸酐 、 2,3,4,5,6-五甲基苯酚 在 氢氧化钾 、 二氧化碳 、 硫酸 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 水 、 水杨酸 为溶剂， 以1.35 g (64.9%)的产率得到3,4,5,6-tetramethylsalicylic acid
  参考文献：
  名称：

  Analogues of acetylsalicylic acid and novel uses thereof

  摘要：

  本发明提供了一种水杨酸类似物，其结构为##STR1##其中R选自氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基、戊基、己基、庚基、壬基、癸基、十一基、苯基、萘基和环己基等基团；其中R1选自氢、C1-C12烷基、F、Cl、Br、I、CO.sub.2 H、CONHR、CONR.sub.2、CO.sub.2 R、C.tbd.N、CHO、COR、SO.sub.3、SO.sub.2 NHR、SO.sub.2 NR.sub.2、OH、OR、OCOR、SH、SR、OCONHR、OCONR.sub.2、SCOR、SCONHR、SCONR.sub.2、NH2、NHR、NHCOR和NR2等基团；其中R1位于3-、4-、5-或6-位，或其组合位置。本发明还提供了各种新化合物的药物组合物。

  公开号：

  US05599959A1

文献信息

• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS
  申请人：Deliencourt-Godefroy Geraldine

  公开号：US20140105839A1

  公开（公告）日：2014-04-17

  The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.

  本发明涉及以下式(I)的化合物，以及其制备方法，包括该化合物的药物和化妆品组合物及其用途，特别是作为钠依赖性葡萄糖共转运体的抑制剂，例如SGLT1、SGLT2和SGLT3，特别用于治疗或预防糖尿病，尤其是2型糖尿病、糖尿病相关并发症，如下肢关节炎、心肌梗死、肾功能不全、神经病变或失明、高血糖、高胰岛素血症、肥胖症、高甘油三酯血症、X综合征和动脉硬化，以及用作抗癌、抗感染、抗病毒、抗血栓或抗炎药物，或用于美白、漂白、去色素的皮肤、去除皮肤瑕疵，特别是老年斑和雀斑，或预防皮肤色素沉着。
• ENGINE LUBRICANT COMPOSITION
  申请人：Obrecht Nicholas

  公开号：US20130244917A1

  公开（公告）日：2013-09-19

  Lubricant compositions include: (a) one or more polyalkylene glycol base oils obtained by polymerization or copolymerization of alkylene oxides comprising from 3 to 8 carbon atoms, include at least one butylene oxide and (b) at least one detergent chosen from salicylates or phenates. The present disclosure also relates to: 1) use of a lubricant composition as engine oil, preferably as oil for the engines of petrol or diesel motor vehicles; 2) use of a group of additives for an engine lubricant comprising polyalkylene glycol bases obtained by polymerization or copolymerization of alkylene oxides comprising from 3 to 8 carbon atoms; and 3) use of at least one additive chosen from salicylates, phenates, dithiocarbamates, amine-based or phenol-based antioxidants, preferably from salicylates or phenates, for reducing the Noack volatility of the base oils of polyalkylene glycol type, obtained from alkylene oxides comprising from 3 to 8 carbon atoms.
• US5599959A
  申请人：——

  公开号：US5599959A

  公开（公告）日：1997-02-04
• US9434670B2
  申请人：——

  公开号：US9434670B2

  公开（公告）日：2016-09-06